Skip to main content
. Author manuscript; available in PMC: 2019 Nov 13.
Published in final edited form as: Circulation. 2018 Nov 13;138(20):2247–2262. doi: 10.1161/CIRCULATIONAHA.117.032821

Figure 6.

Figure 6.

Effects of Tat-beclin-1 peptide (TB-peptide) in LPS-challenged mice. WT and Becn1+/− mice were given 5 mg/kg (A-C) or 10 mg/kg (D) LPS i.p. TB-peptide, 16 mg/kg, was administered i.p. 30 minutes post LPS challenge. Cardiac function was measured and tissues collected 18 hours post LPS challenge. A. Levels of LC3II, p62 and GAPDH were analyzed by Western blots using GAPDH as a loading control in heart tissue lysates. B. Cardiac function was examined by echocardiography. C. Cytokines in serum were measured by ELISA assays. In A-C, all values are means ± SEM. Significant differences are shown as * for with sham vs. LPS-treated, Δ for vehicle vs. TB-peptide-treated, and ¶ for WT vs. Becn1+/− groups (p < 0.05, n = 5, Mann-Whitney U test). D. Survival was monitored in LPS (10 mg/kg)-challenged WT ± TB-peptide and Becn1+/− mice, and * indicates a statistical significance when compared with WT (p < 0.05, n = 12, log-rank test).